Valeo Pharma Inc
TSX:VPH
Valeo Pharma Inc
Cost of Revenue
Valeo Pharma Inc
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Valeo Pharma Inc
TSX:VPH
|
Cost of Revenue
-CA$40.8m
|
CAGR 3-Years
-89%
|
CAGR 5-Years
-63%
|
CAGR 10-Years
N/A
|
|
Bausch Health Companies Inc
TSX:BHC
|
Cost of Revenue
-$2.6B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
Theratechnologies Inc
TSX:TH
|
Cost of Revenue
-$20.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-16%
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Cost of Revenue
-CA$178.6m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-144%
|
CAGR 10-Years
N/A
|
Spectral Medical Inc
TSX:EDT
|
Cost of Revenue
-CA$1.1m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-2%
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Cost of Revenue
-$4.2m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-34%
|
See Also
What is Valeo Pharma Inc's Cost of Revenue?
Cost of Revenue
-40.8m
CAD
Based on the financial report for Oct 31, 2023, Valeo Pharma Inc's Cost of Revenue amounts to -40.8m CAD.
What is Valeo Pharma Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-63%
Over the last year, the Cost of Revenue growth was -90%. The average annual Cost of Revenue growth rates for Valeo Pharma Inc have been -89% over the past three years , -63% over the past five years .